CY1112353T1 - Παραγωγα μεταστινης και χρηση αυτων - Google Patents

Παραγωγα μεταστινης και χρηση αυτων

Info

Publication number
CY1112353T1
CY1112353T1 CY20111101116T CY111101116T CY1112353T1 CY 1112353 T1 CY1112353 T1 CY 1112353T1 CY 20111101116 T CY20111101116 T CY 20111101116T CY 111101116 T CY111101116 T CY 111101116T CY 1112353 T1 CY1112353 T1 CY 1112353T1
Authority
CY
Cyprus
Prior art keywords
metastatin
activity
secretion
suppressing
present
Prior art date
Application number
CY20111101116T
Other languages
Greek (el)
English (en)
Inventor
Taiji Asami
Naoki Nishizawa
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37846230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112353(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1112353T1 publication Critical patent/CY1112353T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
CY20111101116T 2005-12-22 2011-11-18 Παραγωγα μεταστινης και χρηση αυτων CY1112353T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005370388 2005-12-22
JP2006275843 2006-10-06
EP06843555A EP1963362B1 (en) 2005-12-22 2006-12-21 Metastin derivatives and use thereof

Publications (1)

Publication Number Publication Date
CY1112353T1 true CY1112353T1 (el) 2015-12-09

Family

ID=37846230

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101116T CY1112353T1 (el) 2005-12-22 2011-11-18 Παραγωγα μεταστινης και χρηση αυτων

Country Status (29)

Country Link
US (1) US7960348B2 (OSRAM)
EP (1) EP1963362B1 (OSRAM)
JP (2) JP4653840B2 (OSRAM)
KR (1) KR101368607B1 (OSRAM)
AR (1) AR058584A1 (OSRAM)
AU (1) AU2006328333B2 (OSRAM)
BR (1) BRPI0619399B8 (OSRAM)
CA (1) CA2634647C (OSRAM)
CR (1) CR10019A (OSRAM)
CY (1) CY1112353T1 (OSRAM)
DK (1) DK1963362T3 (OSRAM)
ES (1) ES2375038T3 (OSRAM)
GE (1) GEP20115356B (OSRAM)
HR (1) HRP20110851T1 (OSRAM)
IL (1) IL190888A (OSRAM)
JO (1) JO2799B1 (OSRAM)
MA (1) MA30060B1 (OSRAM)
ME (1) ME01015B (OSRAM)
MY (1) MY151967A (OSRAM)
NO (1) NO341879B1 (OSRAM)
NZ (1) NZ568322A (OSRAM)
PE (1) PE20071141A1 (OSRAM)
PL (1) PL1963362T3 (OSRAM)
PT (1) PT1963362E (OSRAM)
RS (1) RS52007B (OSRAM)
RU (1) RU2430107C2 (OSRAM)
SI (1) SI1963362T1 (OSRAM)
TW (1) TWI386417B (OSRAM)
WO (1) WO2007072997A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
WO2004080479A1 (ja) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 性腺機能改善剤
PE20060371A1 (es) 2004-06-25 2006-06-15 Takeda Pharmaceutical Derivados de metastina en el tratamiento del cancer
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
JO3048B1 (ar) * 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
EP2277900A4 (en) * 2008-04-24 2011-08-03 Takeda Pharmaceutical METASTINE DERIVATIVE AND ITS USE
SMT201700131T1 (it) 2008-07-30 2017-05-08 Takeda Pharmaceuticals Co Derivato di metastina e suo uso
EP2379053A1 (en) * 2008-12-29 2011-10-26 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
NZ600157A (en) * 2009-12-22 2013-07-26 Takeda Pharmaceutical Sustained-release formulation comprising metastin derivative
MX2012014265A (es) 2010-06-25 2013-01-18 Takeda Pharmaceutical Formulacion de liberacion sostenida.
EP2755690B1 (en) 2011-08-04 2020-04-01 Merck Sharp & Dohme B.V. Kisspeptide-pentasaccharide conjugates
US9517210B2 (en) 2012-07-12 2016-12-13 Takeda Pharmaceutical Company Limited Method for producing microcapsule powder
US10220069B2 (en) * 2014-01-22 2019-03-05 The Johns Hopkins University Compositions and methods for treating diabetes
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
TWI778979B (zh) 2016-09-30 2022-10-01 瑞士商麥歐文科學有限公司 治療女性不孕症之方法
JP7043503B2 (ja) 2016-09-30 2022-03-29 ミオバント サイエンシズ ゲーエムベーハー 子宮筋腫及び子宮内膜症を治療する方法
TWI810193B (zh) * 2017-07-05 2023-08-01 大陸商尚華醫藥科技（江西）有限公司 一種Kiss1肽類化合物、其應用及含其的組合物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74827A (en) 1984-05-21 1989-06-30 Salk Inst For Biological Studi Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es) 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
JPH09169735A (ja) 1995-10-19 1997-06-30 Takeda Chem Ind Ltd キノリン誘導体、その製造法および用途
EP0876349B1 (en) 1995-10-19 2002-09-11 Takeda Chemical Industries, Ltd. Quinoline derivatives as gnrh antagonists
EP0910579A1 (en) 1996-04-19 1999-04-28 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CN1359297A (zh) 1999-06-28 2002-07-17 巴斯福股份公司 预防肿瘤生长的方法
EP1200553B1 (en) 1999-08-02 2009-07-15 Archer-Daniels-Midland Company Metabolic engineering of amino acid production
CA2394404A1 (en) 1999-12-17 2001-06-21 Takeda Chemical Industries, Ltd. Process for producing kiss-1 peptide
CA2404233A1 (en) 2000-03-29 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2001244609A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Novel protein, dna thereof and process for producing the same
US7834141B1 (en) 2000-03-31 2010-11-16 Theresa Siler-Khodr Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru) 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja) 2000-11-29 2003-01-29 Takeda Chem Ind Ltd 医薬組成物およびその製造法
JP2002320496A (ja) 2001-02-26 2002-11-05 Takeda Chem Ind Ltd 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
JP2003070488A (ja) 2001-05-17 2003-03-11 Takeda Chem Ind Ltd ペプチドの製造法
WO2003027149A1 (fr) 2001-09-19 2003-04-03 Takeda Chemical Industries, Ltd. Anticorps et utilisation de ce dernier
CA2472423A1 (en) 2002-01-11 2003-07-24 Takeda Chemical Industries, Ltd. Process for producing kiss-1 peptide
JP2003300906A (ja) 2002-04-12 2003-10-21 Daiichi Fine Chemical Co Ltd がん転移抑制因子の安定化
EP1554382B1 (en) 2002-10-25 2009-04-22 Takeda Pharmaceutical Company Limited Gpr54 knock-out mammals and screening methods using them
CN1761680A (zh) 2002-12-26 2006-04-19 武田药品工业株式会社 肿瘤迁移抑制素衍生物及其用途
JP4804714B2 (ja) * 2002-12-26 2011-11-02 武田薬品工業株式会社 メタスチン誘導体およびその用途
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
KR100595364B1 (ko) 2003-02-20 2006-07-03 재단법인 목암생명공학연구소 Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
WO2004080479A1 (ja) 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited 性腺機能改善剤
EP1464652A1 (en) 2003-04-02 2004-10-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
US20050002935A1 (en) 2003-04-17 2005-01-06 Vincent Ling Use of B7-H3 as an immunoregulatory agent
AU2004234399A1 (en) 2003-04-28 2004-11-11 Wyeth Methods utilising G-protein coupled receptor 54
WO2004101747A2 (en) 2003-05-07 2004-11-25 The General Hospital Corporation Identification and use of gpr54 and its ligands for reproductive disorders and contraception
US20070155803A1 (en) 2003-05-30 2007-07-05 Prozymex A/S Protease inhibitors
RU2333221C2 (ru) 2003-11-03 2008-09-10 Бейцзин Санбио Байотек Ко., Лтд. Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение
EP1688498B1 (en) 2003-11-03 2011-03-09 Beijing Sunbio Biotech Co., Ltd. A recombinant protein with cancer suppression action, its encoding gene and use
WO2005095973A2 (en) 2004-03-25 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
PE20060371A1 (es) * 2004-06-25 2006-06-15 Takeda Pharmaceutical Derivados de metastina en el tratamiento del cancer
US7725869B1 (en) 2005-04-07 2010-05-25 Xilinx, Inc. Method and apparatus for modeling multiple instances of an electronic circuit using an imperative programming language description
WO2007084211A2 (en) 2005-11-11 2007-07-26 The General Hospital Corporation Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090099334A1 (en) 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها

Also Published As

Publication number Publication date
KR101368607B1 (ko) 2014-02-27
NZ568322A (en) 2010-12-24
RU2430107C2 (ru) 2011-09-27
CR10019A (es) 2008-07-29
PL1963362T3 (pl) 2012-04-30
SI1963362T1 (sl) 2011-12-30
KR20080086438A (ko) 2008-09-25
EP1963362A1 (en) 2008-09-03
HK1120809A1 (en) 2009-04-09
JP5298087B2 (ja) 2013-09-25
EP1963362B1 (en) 2011-08-24
RS52007B (sr) 2012-04-30
CA2634647A1 (en) 2007-06-28
CA2634647C (en) 2014-01-28
NO341879B1 (no) 2018-02-12
GEP20115356B (en) 2011-12-26
US7960348B2 (en) 2011-06-14
BRPI0619399B8 (pt) 2021-05-25
PT1963362E (pt) 2011-10-17
AU2006328333B2 (en) 2011-11-17
MA30060B1 (fr) 2008-12-01
HRP20110851T1 (hr) 2011-12-31
RU2008125063A (ru) 2009-12-27
JP4653840B2 (ja) 2011-03-16
BRPI0619399A2 (pt) 2013-01-08
AR058584A1 (es) 2008-02-13
IL190888A0 (en) 2008-11-03
JO2799B1 (en) 2014-03-15
BRPI0619399B1 (pt) 2019-07-09
NO20082595L (no) 2008-09-22
ES2375038T3 (es) 2012-02-24
ME01015B (me) 2012-10-20
DK1963362T3 (da) 2011-09-19
JP2010265311A (ja) 2010-11-25
TW200804414A (en) 2008-01-16
MY151967A (en) 2014-07-31
PE20071141A1 (es) 2008-01-07
US20100331520A1 (en) 2010-12-30
TWI386417B (zh) 2013-02-21
JP2009520682A (ja) 2009-05-28
WO2007072997A1 (en) 2007-06-28
IL190888A (en) 2014-07-31
AU2006328333A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
CY1112353T1 (el) Παραγωγα μεταστινης και χρηση αυτων
CY1116627T1 (el) Παραγωγα μεταστινης και χρηση αυτων
CY1120564T1 (el) Υδατικα εναιωρηματα tmc278
CY1124011T1 (el) Συνθεσεις γλυκοπεπτιδιου
TW200607816A (en) Metastin derivatives and use thereof
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2020008754A (es) Compuestos farmaceuticos.
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1105608T1 (el) Φαρμακευτικες συνθεσεις παραγωγου του λευκοχρυσου
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1106824T1 (el) Σταθερες ενεσιμες συνθεσεις δικλοφενακ
CY1120081T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
GEP20105074B (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
WO2014096985A3 (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
TR201903610T4 (tr) Alfa-melanosit uyarici hormonlarin peptid analoglari.
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
CY1108246T1 (el) ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ
SA522431304B1 (ar) عمليات تحضير اللاسميديتان وملح الأسيتات منه
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
SA522431498B1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
AR117707A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf